Martin A. Graham

Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models

Christopher A. Benetatos, Yasuhiro Mitsuuchi, Jennifer M. Burns et al. · Molecular Cancer Therapeutics · 2014 · 175 citations

Life Sciences, Oncology, Pharmacology +17

Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies

Stephen M. Condon, Yasuhiro Mitsuuchi, Yijun Deng et al. · Journal of Medicinal Chemistry · 2014 · 151 citations

Medicine, Oncology, Pharmacology +13

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

Yvonne S. Lin, G. Lockwood, Martin A. Graham et al. · Pharmacogenetics · 2001 · 134 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Ravi K. Amaravadi, Russell J. Schilder, Lainie P. Martin et al. · Molecular Cancer Therapeutics · 2015 · 134 citations

Medicine, Oncology, Pharmacology +17

Temporal and Spatial Evolution of Therapy-Induced Tumor Apoptosis Detected by Caspase-3–Selective Molecular Imaging

Quang-Dé Nguyen, Ioannis Lavdas, James Gubbins et al. · Clinical Cancer Research · 2013 · 55 citations

Medicine, Oncology, Pharmacology +17